We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Marvell (MRVL) to Post Q3 Earnings: What's in the Offing?
Read MoreHide Full Article
Marvell Technology Group Ltd. (MRVL - Free Report) is set to report third-quarter fiscal 2020 results on Dec 3.
Marvell projects revenues of $660 million, up or down up to 3%. The Zacks Consensus Estimate for the same is pegged at $660.2 million, suggesting a 22.42% decline from the year-ago reported figure.
The company anticipates non-GAAP earnings per share in the band of 15-19 cents. The consensus mark stands at 17 cents, indicating a 48.48% decline.
The company surpassed the Zacks Consensus Estimate thrice in the trailing four quarters, and missed it once, the average positive surprise being 3.16%.
Marvell Technology Group Ltd. Price and EPS Surprise
In the fiscal second quarter, non-GAAP earnings of 16 cents beat the consensus estimate of 15 cents but declined 43% from the year-ago quarter.
Marvell’s revenues of $657 million surpassed the consensus estimate of $650 million. However, the figure declined 1.2% year over year.
Factors at Play
An increase in demand for storage controllers from the data center and enterprise markets is likely to have boosted Marvell’s third-quarter performance. Demand, particularly from high-capacity nearline drives, combined with some improvement in the SSD market after a period of under shipment, is expected to have been a tailwind for storage revenues.
Moreover, slight seasonal growth in HDDs for PCs in gaming is likely to have resulted in an approximate high single-digit sequential rise in fiscal third-quarter storage revenues. The Zacks Consensus Estimate for storage revenues is pegged at $296 million, suggesting 7.6% sequential growth.
Further, demand for fiber channel adapter is also expected to have grown in the quarter.
The seasonal decline in WiFi revenues is likely to have been partially offset by growth in the company’s base station products, driven by the commencement of 5G production shipments.
Continued design wins are also expected to have positively impacted the top line in the quarter.
Moreover, Marvell’s continued efforts to optimize operating expenses are likely to have taken the steam off the margins.
However, continued weak macroeconomic conditions and impact of the export restrictions and accounting for the customer factory transition might have been an overhang on networking revenues. Management expects a low-single digit sequential decline in the same.
Seasonal decline in Wi-Fi revenues is also expected to have been an overhang on fiscal third-quarter top line.
Furthermore, sluggishness in the global chip industry is likely to have been an overhang. This is because of the company’s significant dependence on semiconductor sales for revenues.
Also, other product revenues are expected to have declined sequentially after a strong second-quarter fiscal 2020. The Zacks Consensus Estimate for other product revenues is pegged at $45.2 million, suggesting a 13.1% sequential decrease.
Moreover, management expects non-GAAP gross margin to be between 63% and 64%, reflecting a weaker product mix due to the impact of export restriction and low networking revenues. Additionally, the Huawei ban has led the company to expect zero shipments to the telecom equipment maker. This is likely to have further affected the product mix and put pressure on margins.
What Does the Zacks Model Say
The proven Zacks model does not conclusively predict an earnings beat for Marvell this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
Marvell has a Zacks Rank #3 and an Earnings ESP of 0.00%.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Following are a few stocks worth considering with the right mix of elements to beat estimates this time:
Dollar General Corporation (DG - Free Report) has an Earnings ESP of +0.65% and a Zacks Rank of 2.
CarMax, Inc. (KMX - Free Report) has an Earnings ESP of +0.5% and is Zacks #2 Ranked.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Marvell (MRVL) to Post Q3 Earnings: What's in the Offing?
Marvell Technology Group Ltd. (MRVL - Free Report) is set to report third-quarter fiscal 2020 results on Dec 3.
Marvell projects revenues of $660 million, up or down up to 3%. The Zacks Consensus Estimate for the same is pegged at $660.2 million, suggesting a 22.42% decline from the year-ago reported figure.
The company anticipates non-GAAP earnings per share in the band of 15-19 cents. The consensus mark stands at 17 cents, indicating a 48.48% decline.
The company surpassed the Zacks Consensus Estimate thrice in the trailing four quarters, and missed it once, the average positive surprise being 3.16%.
Marvell Technology Group Ltd. Price and EPS Surprise
Marvell Technology Group Ltd. price-eps-surprise | Marvell Technology Group Ltd. Quote
In the fiscal second quarter, non-GAAP earnings of 16 cents beat the consensus estimate of 15 cents but declined 43% from the year-ago quarter.
Marvell’s revenues of $657 million surpassed the consensus estimate of $650 million. However, the figure declined 1.2% year over year.
Factors at Play
An increase in demand for storage controllers from the data center and enterprise markets is likely to have boosted Marvell’s third-quarter performance. Demand, particularly from high-capacity nearline drives, combined with some improvement in the SSD market after a period of under shipment, is expected to have been a tailwind for storage revenues.
Moreover, slight seasonal growth in HDDs for PCs in gaming is likely to have resulted in an approximate high single-digit sequential rise in fiscal third-quarter storage revenues. The Zacks Consensus Estimate for storage revenues is pegged at $296 million, suggesting 7.6% sequential growth.
Further, demand for fiber channel adapter is also expected to have grown in the quarter.
The seasonal decline in WiFi revenues is likely to have been partially offset by growth in the company’s base station products, driven by the commencement of 5G production shipments.
Continued design wins are also expected to have positively impacted the top line in the quarter.
Moreover, Marvell’s continued efforts to optimize operating expenses are likely to have taken the steam off the margins.
However, continued weak macroeconomic conditions and impact of the export restrictions and accounting for the customer factory transition might have been an overhang on networking revenues. Management expects a low-single digit sequential decline in the same.
Seasonal decline in Wi-Fi revenues is also expected to have been an overhang on fiscal third-quarter top line.
Furthermore, sluggishness in the global chip industry is likely to have been an overhang. This is because of the company’s significant dependence on semiconductor sales for revenues.
Also, other product revenues are expected to have declined sequentially after a strong second-quarter fiscal 2020. The Zacks Consensus Estimate for other product revenues is pegged at $45.2 million, suggesting a 13.1% sequential decrease.
Moreover, management expects non-GAAP gross margin to be between 63% and 64%, reflecting a weaker product mix due to the impact of export restriction and low networking revenues. Additionally, the Huawei ban has led the company to expect zero shipments to the telecom equipment maker. This is likely to have further affected the product mix and put pressure on margins.
What Does the Zacks Model Say
The proven Zacks model does not conclusively predict an earnings beat for Marvell this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
Marvell has a Zacks Rank #3 and an Earnings ESP of 0.00%.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Following are a few stocks worth considering with the right mix of elements to beat estimates this time:
Canadian Imperial Bank of Commerce (CM - Free Report) has an Earnings ESP of +0.61% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Dollar General Corporation (DG - Free Report) has an Earnings ESP of +0.65% and a Zacks Rank of 2.
CarMax, Inc. (KMX - Free Report) has an Earnings ESP of +0.5% and is Zacks #2 Ranked.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>